224 related articles for article (PubMed ID: 26288025)
1. Remogliflozin etabonate: a novel SGLT2 inhibitor for treatment of diabetes mellitus.
Mikhail N
Expert Opin Investig Drugs; 2015; 24(10):1381-7. PubMed ID: 26288025
[TBL] [Abstract][Full Text] [Related]
2. Remogliflozin etabonate : a novel SGLT2 inhibitor for treatment of diabetes mellitus.
Mikhail N
Expert Opin Investig Drugs; 2015 Aug; ():1-7. PubMed ID: 26271274
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety of Remogliflozin Etabonate, a New Sodium Glucose Co-Transporter-2 Inhibitor, in Patients with Type 2 Diabetes Mellitus: A 24-Week, Randomized, Double-Blind, Active-Controlled Trial.
Dharmalingam M; Aravind SR; Thacker H; Paramesh S; Mohan B; Chawla M; Asirvatham A; Goyal R; Shembalkar J; Balamurugan R; Kadam P; Alva H; Kodgule R; Tandon M; Vaidyanathan S; Pendse A; Gaikwad R; Katare S; Suryawanshi S; Barkate H
Drugs; 2020 Apr; 80(6):587-600. PubMed ID: 32162274
[TBL] [Abstract][Full Text] [Related]
4. First human dose-escalation study with remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2 (SGLT2), in healthy subjects and in subjects with type 2 diabetes mellitus.
Kapur A; O'Connor-Semmes R; Hussey EK; Dobbins RL; Tao W; Hompesch M; Smith GA; Polli JW; James CD; Mikoshiba I; Nunez DJ
BMC Pharmacol Toxicol; 2013 May; 14():26. PubMed ID: 23668634
[TBL] [Abstract][Full Text] [Related]
5. Remogliflozin etabonate, a selective inhibitor of the sodium-dependent transporter 2 reduces serum glucose in type 2 diabetes mellitus patients.
Dobbins RL; O'Connor-Semmes R; Kapur A; Kapitza C; Golor G; Mikoshiba I; Tao W; Hussey EK
Diabetes Obes Metab; 2012 Jan; 14(1):15-22. PubMed ID: 21733056
[TBL] [Abstract][Full Text] [Related]
6. Randomized trial showing efficacy and safety of twice-daily remogliflozin etabonate for the treatment of type 2 diabetes.
Sykes AP; O'Connor-Semmes R; Dobbins R; Dorey DJ; Lorimer JD; Walker S; Wilkison WO; Kler L
Diabetes Obes Metab; 2015 Jan; 17(1):94-7. PubMed ID: 25223369
[TBL] [Abstract][Full Text] [Related]
7. Randomized efficacy and safety trial of once-daily remogliflozin etabonate for the treatment of type 2 diabetes.
Sykes AP; Kemp GL; Dobbins R; O'Connor-Semmes R; Almond SR; Wilkison WO; Walker S; Kler L
Diabetes Obes Metab; 2015 Jan; 17(1):98-101. PubMed ID: 25238025
[TBL] [Abstract][Full Text] [Related]
8. Remogliflozin Etabonate in the Treatment of Type 2 Diabetes: Design, Development, and Place in Therapy.
Mohan V; Mithal A; Joshi SR; Aravind SR; Chowdhury S
Drug Des Devel Ther; 2020; 14():2487-2501. PubMed ID: 32612352
[TBL] [Abstract][Full Text] [Related]
9. The Role of Sodium-Glucose Co-Transporter 2 Inhibitors in the Treatment of Type 2 Diabetes.
Whalen K; Miller S; Onge ES
Clin Ther; 2015 Jun; 37(6):1150-66. PubMed ID: 25891804
[TBL] [Abstract][Full Text] [Related]
10. Safety, pharmacokinetics and pharmacodynamics of remogliflozin etabonate, a novel SGLT2 inhibitor, and metformin when co-administered in subjects with type 2 diabetes mellitus.
Hussey EK; Kapur A; O'Connor-Semmes R; Tao W; Rafferty B; Polli JW; James CD; Dobbins RL
BMC Pharmacol Toxicol; 2013 Apr; 14():25. PubMed ID: 23631443
[TBL] [Abstract][Full Text] [Related]
11. Remogliflozin etabonate, in a novel category of selective low-affinity sodium glucose cotransporter (SGLT2) inhibitors, exhibits antidiabetic efficacy in rodent models.
Fujimori Y; Katsuno K; Nakashima I; Ishikawa-Takemura Y; Fujikura H; Isaji M
J Pharmacol Exp Ther; 2008 Oct; 327(1):268-76. PubMed ID: 18583547
[TBL] [Abstract][Full Text] [Related]
12. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus.
Scheen AJ
Drugs; 2015 Jan; 75(1):33-59. PubMed ID: 25488697
[TBL] [Abstract][Full Text] [Related]
13. Assessment of safety and tolerability of remogliflozin etabonate (GSK189075) when administered with total daily dose of 2000 mg of metformin.
Dobbins R; Hussey EK; O'Connor-Semmes R; Andrews S; Tao W; Wilkison WO; Cheatham B; Sagar K; Hanmant B
BMC Pharmacol Toxicol; 2021 Jun; 22(1):34. PubMed ID: 34120651
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of novel sodium glucose cotransporter-2 inhibitor remogliflozin in the management of type 2 diabetes mellitus: A systematic review and meta-analysis.
Dutta D; Jindal R; Mehta D; Khandelwal D; Sharma M
Diabetes Metab Syndr; 2021; 15(6):102315. PubMed ID: 34700292
[TBL] [Abstract][Full Text] [Related]
15. Remogliflozin Etabonate: First Global Approval.
Markham A
Drugs; 2019 Jul; 79(10):1157-1161. PubMed ID: 31201711
[TBL] [Abstract][Full Text] [Related]
16. Remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2, improves serum glucose profiles in type 1 diabetes.
Mudaliar S; Armstrong DA; Mavian AA; O'Connor-Semmes R; Mydlow PK; Ye J; Hussey EK; Nunez DJ; Henry RR; Dobbins RL
Diabetes Care; 2012 Nov; 35(11):2198-200. PubMed ID: 23011728
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and Pharmacodynamics of the SGLT2 Inhibitor Remogliflozin Etabonate in Subjects with Mild and Moderate Renal Impairment.
O'Connor-Semmes R; Walker S; Kapur A; Hussey EK; Ye J; Wang-Smith L; Tao W; Dobbins RL; Cheatham B; Wilkison WO
Drug Metab Dispos; 2015 Jul; 43(7):1077-83. PubMed ID: 25934577
[TBL] [Abstract][Full Text] [Related]
18. [Dapagliflozin, the first SGLT-2 inhibitor in the treatment of type 2 diabetes].
Albarrán OG; Ampudia-Blasco FJ
Med Clin (Barc); 2013 Sep; 141 Suppl 2():36-43. PubMed ID: 24444523
[TBL] [Abstract][Full Text] [Related]
19. SGLT2 inhibition: efficacy and safety in type 2 diabetes treatment.
Scheen AJ
Expert Opin Drug Saf; 2015; 14(12):1879-904. PubMed ID: 26513131
[TBL] [Abstract][Full Text] [Related]
20. Canagliflozin, a new sodium-glucose cotransporter 2 inhibitor, in the treatment of diabetes.
Nisly SA; Kolanczyk DM; Walton AM
Am J Health Syst Pharm; 2013 Feb; 70(4):311-9. PubMed ID: 23370138
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
